Dexcom unveiled its "State of Type 2 Report" at ATTD 2025, highlighting that healthcare professionals increasingly favor technology over medication for managing Type 2 diabetes. The report, based on surveys from over 2,500 participants across Europe and the Middle East, underscores the benefits of continuous glucose monitoring (CGM) and calls for improved access to diabetes technology.

The conference also featured the first-ever accuracy and performance data for Dexcom’s upcoming G7 15 Day system, which demonstrated a mean absolute relative difference (MARD) of 8.0%, making it the most accurate CGM sensor. Additionally, Dexcom announced new integrations, including compatibility with the Omnipod 5 Automated Insulin Delivery System and smart insulin pens like NovoPen 6 and NovoPen Echo Plus, reinforcing its position as the most connected CGM brand.

Key findings from the report reveal that 52% of healthcare professionals see CGM and education as the future of Type 2 diabetes management, while 50% believe CGM should be the standard of care for all patients, regardless of insulin use. However, funding constraints and limited inclusion criteria remain major barriers to widespread CGM adoption.

Dexcom continues to advocate for increased investment in CGM technology, emphasizing its potential to enhance patient outcomes, reduce complications, and lower long-term healthcare costs. The Dexcom G7 15 Day system is currently under FDA review and is expected to further improve accuracy and usability.